CC-99677 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
271強直性脊椎炎4

271. 強直性脊椎炎


臨床試験数 : 574 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004108-37-CZ
(EUCTR)
14/10/202109/03/2021A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing SpondylitisA Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis Ankylosing Spondylitis
MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: CC-99677 60mg Capsule
INN or Proposed INN: 146368
Other descriptive name: CC-99677
Product Code: CC-99677 30mg Capsule
INN or Proposed INN: 146368
Other descriptive name: CC-99677
Celgene CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
256Phase 2United States;Czechia;Czech Republic;Canada;Spain;Poland;Turkey;Romania;Russian Federation;Germany
2EUCTR2019-004108-37-PL
(EUCTR)
13/09/202101/04/2021A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing SpondylitisA Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis Ankylosing Spondylitis
MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: CC-99677 60mg Capsule
INN or Proposed INN: 146368
Other descriptive name: CC-99677
Product Code: CC-99677 30mg Capsule
INN or Proposed INN: 146368
Other descriptive name: CC-99677
Celgene CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
256Phase 2United States;Czechia;Czech Republic;Canada;Spain;Poland;Turkey;Romania;Russian Federation;Germany
3NCT04947579
(ClinicalTrials.gov)
August 25, 202123/6/2021A Study of CC-99677 in Participants With Active Ankylosing SpondylitisA Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing SpondylitisSpondylitis, AnkylosingDrug: CC-99677;Other: PlaceboCelgeneNULLTerminated18 Years65 YearsAll167Phase 2United States;China;Czechia;Germany;Poland;Romania;Spain;Turkey;Canada;Russian Federation
4EUCTR2019-004108-37-DE
(EUCTR)
09/07/202118/02/2021A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing SpondylitisA Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis Ankylosing Spondylitis
MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: CC-99677 60mg Capsule
INN or Proposed INN: 146368
Other descriptive name: CC-99677
Product Code: CC-99677 30mg Capsule
INN or Proposed INN: 146368
Other descriptive name: CC-99677
Celgene CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
256Phase 2United States;Czechia;Czech Republic;Canada;Spain;Poland;Turkey;Romania;Russian Federation;Germany